Outcomes for patients with platinum-sensitive recurrent ovarian cancer treated with prolonged PARP inhibitor therapy. - KIVIRID

Outcomes for patients with platinum-sensitive recurrent ovarian cancer treated with prolonged PARP inhibitor therapy.

Authors: Corrine A. Nief, Jonathan S. Berek, Talayeh Ghezelayagh

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17607

Source: Full article

Abstract

e17607